Proud Partners

Welcome to the Inaugural Genetic Vaccine Development for Infectious Diseases Summit

Overcome the Translational Challenges of Developing mRNA, DNA & Engineered Viral Vector-Based Vaccines

The Genetic Vaccine Development for Infectious Diseases Summit will focus on overcoming the translational and clinical challenges of developing genetic vaccines targeting infectious diseases.

The agenda will cover clinical trial updates for pregnant women on COVID-19 candidates and long-term correlates of protection, plus our expert speakers will share unpublished data on gene-based vaccines for a wide range of infectious diseases, including Influenza, Lassa fever, Ebola, MERS, HIV, Zika, and COVID-19.

With a focus on mRNA, DNA, and engineered viral vector-based vaccines, this niche 3-day agenda has been specifically designed to help industry experts to:

Untitled design (40)

Progress your own expertise and forge powerful collaborations with leading biotech, pharma, academics & NPOs

Untitled design (40)

Overcome immunogenicity challenges to design safe and efficacious vaccine formulations

Untitled design (40)

Define clinically meaningful endpoints to successfully develop and safely deliver optimal doses for public use

Form Powerful Collaborations with Pioneering Biopharma

The digital Genetic Vaccine Development for Infectious Diseases Summit is not only the first, but the only industry-dedicated meeting that brings you the most up-to-date clinical and commercial developments utilizing next-generation vaccine technologies for infectious diseases.  

Join 100+ experts online from companies such as BioNTech, Pfizer, Moderna, AstraZeneca, CureVac and more to discuss new genetic-based vaccine platforms, preclinical and clinical case studies, optimized delivery methods, and the future of vaccine R&D to usher in a new era of vaccinology.

29 World-Class Speakers, Including:

Andreas Kuhn, PhD

Sr. VP, RNA Biochemistry & Manufacturing


Johan Vekemans, PhD

Global Clinical Head, SARS-CoV-2 Vaccine


Lidia Oostvogels, PhD

VP Area Head Infectious Diseases


Jason DeHart, PhD

Senior Principal Scientist, RNA & Targeted Therapeutics


Jacqueline Miller, MD

Sr. VP Therapeutic Area Head, Infectious Diseases


Dan Barouch , PhD., MD.,

William Bosworth Castle Professor of Medicine

Harvard Medical School

Kate Broderick, PhD

Sr. VP, R&D


Louis Picker, PhD

Associate Director & Professor

Vaccine and Gene Therapy Institute, OHSU

Norman Begg, PhD

Former Chief Medical Officer

GSK Vaccines

Philip Dormitzer, PhD

Vice President & Chief Scientific Officer: Viral Vaccines


Pre-Conference Symposium: SARS-CoV-2

By May, millions of doses of SARS-CoV-2 vaccines will have been administered. We have curated a tailored and focused program specifically on the SARS-CoV-2 pathogen to bring you updates on safety and effectiveness, correlates of protection, duration of long-term immunity, and use in potentially at-risk population groups such as pregnant women, children, and allergy sufferers

Tuesday, May 18 (AM)

Tuesday, May 18 (PM)

9:00 Update on Clinical Trials Involving Pregnant Women with COVID-19 Vaccines

9:30 Controlled Human Infection Models to Further Validate the Efficacy of COVID-19 Vaccines

10:00 Development of an mRNA-based COVID-19 Vaccine at ‘lightspeed’: From Pre-Clinical Studies to Large-scale Manufacture

10:30 Moderna’s COVID-19 Vaccine: A Summary of Available Clinical Data

11:30 Clinical and Operational Challenges of COVID-19 Vaccine Development and Future Opportunities

12:00 INO-4800 – A DNA based Vaccine Against COVID-19

12:30 CVnCov: CureVac’s mRNA-based Vaccine Candidate Against COVID-19

2:00 Immunogenicity of Chimpanzee Adenovirus Vector Vaccines Expressing SARS-CoV2 Spike and Nucleocapsid

2:30 Development of AAVCOVID: A Single Dose AAV-based Vaccine for COVID-19

3:00 A Framework to Analyse the Pandemic Potential of Pathogens: COVID-19 and Future Directions

What Do Our Speakers Have To Say?

"The vaccine landscape has been revolutionised by the advent of genetic vaccines. I am delighted to participate in this summit, to better understand how these powerful new tools can contribute to global public health"

- Norman Begg, Chief Medical Officer Emeritus, GSK Vaccines


"It was so well organized that it almost felt like you were there in person, and the sessions moved flawlessly" 

- Cerevel Therapeutics from the Gene Therapy Series